Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance.

ABSTRACT:

Background

Although patient factors and sequential anthracycline use contribute to risk for cancer therapy-related cardiac dysfunction (CTRCD) with HER2-directed cancer therapy, frequent (every 3 months) left ventricular ejection fraction (LVEF) surveillance is recommended irrespective of baseline risk.

Objectives

The aim of this study was to examine the incidence of trastuzumab-associated CTRCD in a contemporary cohort with HER2-positive breast cancer and assess the performance of a risk assessment tool to identify patients at low risk for CTRCD to guide risk-based surveillance strategies.

Methods

A retrospective cohort of patients with HER2-positive breast cancer treated with trastuzumab at a tertiary cancer center was examined. Patients were categorized as low, med

SUBMITTER: Ali A 

PROVIDER: S-EPMC12046757 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature